| Literature DB >> 34943117 |
Claudia Rebeca Rivera-Yañez1, Porfirio Alonso Ruiz-Hurtado2, María Isabel Mendoza-Ramos3,4, Julia Reyes-Reali3,4, Gina Stella García-Romo3,4, Glustein Pozo-Molina3,5, Aldo Arturo Reséndiz-Albor6, Oscar Nieto-Yañez3, Adolfo René Méndez-Cruz3,4, Claudia Fabiola Méndez-Catalá5,7, Nelly Rivera-Yañez3,7.
Abstract
The skin is the main external organ. It protects against different types of potentially harmful agents, such as pathogens, or physical factors, such as radiation. Skin disorders are very diverse, and some of them lack adequate and accessible treatment. The photoaging of the skin is a problem of great relevance since it is related to the development of cancer, while psoriasis is a chronic inflammatory disease that causes scaly skin lesions and deterioration of the lifestyle of people affected. These diseases affect the patient's health and quality of life, so alternatives have been sought that improve the treatment for these diseases. This review focuses on describing the properties and benefits of flavonoids from propolis against these diseases. The information collected shows that the antioxidant and anti-inflammatory properties of flavonoids play a crucial role in the control and regulation of the cellular and biochemical alterations caused by these diseases; moreover, flavones, flavonols, flavanones, flavan-3-ols, and isoflavones contained in different worldwide propolis samples are the types of flavonoids usually evaluated in both diseases. Therefore, the research carried out in the area of dermatology with bioactive compounds of different origins is of great relevance to developing preventive and therapeutic approaches.Entities:
Keywords: antioxidant enzymes; flavonoids; oxidative stress; photoaging; propolis; psoriasis
Year: 2021 PMID: 34943117 PMCID: PMC8698766 DOI: 10.3390/antiox10122014
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Basic flavonoid structure.
Anti-photoaging properties of flavones reported in in vitro and in vivo models.
| Flavones | Model/UV Radiation | Activities | Ref. |
|---|---|---|---|
| Luteolin, chrysin, and apigenin | HDFs/UVA | All flavonoids inhibit the MMP-1 mRNA levels; presents antioxidant activity | [ |
| Luteolin | Decreases the MMP-1 expression, the IL-6 secretion, and the hyaluronidase activity | [ | |
| HaCaT cells/SSR | Suppresses the IL-20 production; the HaCaT supernatants pretreated and added to fibroblasts decrease MMP-1 and IL-6 expression | ||
| Skin explants/SSR | Decreases MMP-1 and IL-6 expression | ||
| HaCaT cells/UVB | Inhibits CPDs and ROS production; suppresses the p38 MAPK and ERK activation; decreases COX-2 expression and the PGE2 synthesis | [ | |
| Suppresses MMP-1 expression, AP-1 and c-Fos activation, c-Jun phosphorylation, p90RSK and JNK1 activity, and MMP-1 expression | [ | ||
| Luteolin and apigenin | HaCaT cells/UVA | Both suppress ROS generation and MMP-1 production; inhibit c-Jun and c-Fos expression and the MAP kinases phosphorylation; reduce the influx of Ca2+ and Ca2+/calmodulin-dependent kinases phosphorylation | [ |
| Chrysin | HDFs/UVB | Increases collagen I secretion and the GSH level; decreases the MDA and MMP-1 level | [ |
| HaCaT cells/UVA and UVB | Decreases ROS generation, COX-2 expression, and apoptosis; increases AQP-3 expression; suppresses p38 and JNK activation | [ | |
| Baicalein | HDFs/UVB | Inhibits the 12-lipoxygenase and through the TRPV1-Ca-ERK pathway suppresses the MMP-1 expression | [ |
| Baicalin | Reduces the p16INK−4a, p21WAF−1, p53, and γ-H2AX proteins level | [ | |
| C57BL/6 mice/UVB | Decreases skin thickening; reduces MMP-3 and MMP-1 expression; increases collagen III and I production | ||
| HDFs/UVA | Increases the telomere length, the TGF-β1 secretion, the GPx and SOD levels, and the c-myc mRNA expression and protein level; decreases MDA levels, p16, p53, p66, TIMP-1, MMP-1 mRNA expression, and the p16 and p53 proteins level | [ | |
| HaCaT cells/UVB | Suppresses the CPDs and apoptosis; reduces the c-fos and p53/p21 mRNA expression, the p53, the RPA, and PCNA proteins level, and TNF-α and IL-6 secretion | [ | |
| BALB/c mice/UVB | Reduces skin hyperplasia and edema, hydrogen peroxide generation, and photolesions formation | [ | |
| C3H/HeN mice/UVA | Decreases the CD11b+Gr1+ myeloid-derived suppressor cells, the TLR4 expression level, TRAF6, IRAK4, and MyD88 protein expression, TIRAP and MyD88 mRNA expression, MMP-1 and MMP-9 expression levels, COX-2, IL-1β, IL-10, and iNOS | [ |
Main anti-photoaging effects of flavonols in different study models.
| Flavonols | Model/UV Radiation | Activities | Ref. |
|---|---|---|---|
| Quercetin, myricetin, and kaempferol | HDFs/UVA | All flavonoids inhibit MMP-1 mRNA levels; presents antioxidant activity | [ |
| Galangin, kaempferol and quercetin | EpiDermTM/UVA or UVB | All flavonoids reduce MMP-1 and TNF-α secretion; pretreatment reduces the cyclobutane thymine dimers in UVB-irradiation | [ |
| Myricetin | PHKC/UVB | Decreases MDA level; suppresses H2O2 production and JNK activation | [ |
| Hairless mice/UVB | Decreases epidermal thickening; inhibits enzyme activity and MMP-9 protein expression; inhibits Raf kinase activity and, consequently, decreases MEK and ERK phosphorylation | [ | |
| Quercetin and Quercetin nanoparticles | HaCaT cells/UVB | Both decrease NF-κB protein; suppress the IkB-α phosphorylation; reduce the COX-2 protein expression level | [ |
| C57BL/6 mice/UVB | Decreases IkB-α phosphorylation, COX-2 expression, and PGE2 concentration | ||
| Quercetin | PHKC/UVA and UVB | Reduces NF-κB DNA-binding; inhibits TNF-α, IL-1β, IL-6, and IL-8 expression | [ |
| Human abdominal skin tissue/UVA and UVB | Inhibits COX-2, MMP-1, and collagen degradation; suppresses NF-κB and AP-1 activation, and JAK2 and PKCδ kinase activity; decreases the Akt, JNK, ERK, and STAT3 phosphorylation | [ | |
| Hairless mice/UVB | Decreases MPO activity, increases GSH, and suppresses proteinases secretion/activity | [ | |
| Quercitrin | JB6 cells/UVB | Suppresses apoptosis; reduces C-caspase-3 and C-PARP1 activation; decreases NF-κB activation, DNA damage, 8-OHdG production, γ-H2AX expression, and superoxide radical production; inhibits hydroxyl radical and hydrogen peroxide productions; increases SOD and CAT expressions | [ |
| Hairless mice/UVB | Decreases apoptosis, C-caspase-3 and C-PARP1 expression; DNA damage; 8-OHdG production; and γ-H2AX expression; increases XPA, SOD and CAT expression and GSH levels | ||
| Fisetin | HDFs/UVB | Inhibits collagen degradation, MMP-9, MMP-3, and MMP-1 expression, COX-2, NO generation, the PGE2 and intracellular ROS, NF-κB translocation into the nucleus and the CREB phosphorylation level; decreases JNK and ERK expression, p38 phosphorylation, and IκB degradation | [ |
Anti-photoaging activity of the flavanones.
| Flavanones | Model/UV Radiation | Activities | Ref. |
|---|---|---|---|
| Hesperetin | HDFs/UVA | Decreases ROS generation; reduces collagen depletion and MMP-1 activity; positively regulates Nrf2 activity and its genes NQO-1 and GST | [ |
| BALB/c mice/UVA | Decreases collagen loss, MMP-1 activity, and 8-OhdG; increases nuclear Nrf2 levels and its NQO-1 and GST target proteins | ||
| Hesperidin | HaCaT cells/UVA | Increases SOD activity and total antioxidative capacity levels; reduces MDA content; decreases IL-1β, IL-6, and TNF-α mRNA levels and proteins expression | [ |
| Hairless mice/UVB | Decreases collagen fiber loss, wrinkle formation, and TEWL; suppresses MMP-9 activity and mRNA levels, TNF-α and IL-8 production, and ERK and MEK phosphorylation | [ | |
| Naringenin | HaCaT cells/UVB | Suppresses MMP-1 expression, AP-1 activity, FRA1 expression and phosphorylation, p90RSK phosphorylation, and ERK2 activity | [ |
| Hairless mice/UVB | Suppresses TEWL, wrinkle formation, and MMP-13 expression | ||
| Inhibits the IL-1β, IL-10, IL-6, and TNF-α production; suppresses lipid hydroperoxides and superoxide anion production; preserves GSH levels and CAT activity, Nrf2 mRNA expression, glutathione reductase, and GPx | [ |
Main anti-photoaging functions of flavan-3-ols and isoflavones.
| Flavonoids | Model/UV Radiation | Activities | Ref. |
|---|---|---|---|
| EGCG and EGCG nanoparticles | HaCaT cells/UVB | Both decrease the intracellular ROS levels, MDA level, and MMP-2 and MMP-9 expression | [ |
| EGCG | Reduces apoptosis; suppresses c-fos, p21, and p53 mRNA expression; decreases TNF-α and IL-6 secretion | [ | |
| HDFs/UVB | Inhibits collagen degradation, MAPK, ERK1/2, p38 MAPK, and JNK phosphorylation and ASK-1 activation; the pre-administration suppresses MMP-13, MMP-8, and MMP-1 production | [ | |
| Rats/UVA | Diminution in sunburn cells and dermo-epidermal activation | [ | |
| Catechin | Increases CAT, GPx, and SOD levels; decreases TBRAS levels | [ | |
| Genistein | HDFs/UVB | Reduces the apoptosis and MDA level; increases SOD activity; decreases the p66Shc and FKHRL1 level and phosphorylation | [ |
Propolis from different countries and some of its identified flavonoids with anti-photoaging properties.
| Propolis/Flavonoids | Model/UV Radiation | Identified | Activities | Ref. |
|---|---|---|---|---|
| Brazil | HDFs/ | N.I. | Inhibits intracellular ROS generation, and ERK and p38 phosphorylation level | [ |
| N.I. | Positively modulates early HO-1 expression; induces | [ | ||
| Iran | HDFs/ | N.I. | Raises NGF and FOXO3A gene expression; reduces b-galactosidase activity; presents outstanding antioxidant activity | [ |
| Korea/apigenin, and quercetin | Catechin, naringenin, apigenin, and quercetin | Propolis inhibits MMP-1 production, mRNA levels, and | [ | |
| Korea | HaCaT cells/ | N.I. | Suppresses apoptosis, C-caspase-3 expression; decreases the loss of mitochondrial membrane potential and ROS production | [ |
| Greece | HaCaT cells/ | N.I. | In HaCaT cells, presents antioxidant activity; reduces DNA | [ |
| Romania | Swiss mice/ | Luteolin, kaempferol and apigenin | Reduces MDA and IL-6 levels, C-caspase-3 activation, sunburn cell formation, and CPDs generation; increases GPx activity | [ |
N.I. = No Identified.
Beneficial properties of flavones in different psoriasis models.
| Flavones | Model/Psoriasis Inducer | Activities | Ref. |
|---|---|---|---|
| Luteolin | NHEKs and HaCaT cells | Inhibits mRNA expression of IL-8 and IL-6; reduces mRNA expression of NFKB1 and RELA and HaCaT cell proliferation | [ |
| HaCaT cells | Inhibits transcriptional expression of HSP90β and HSP90α; decreases exosomes amount | [ | |
| BALB/c mice/ | Reduces psoriatic area, PASI, histological damage, and HSP90β and HSP90α expression; decreases the proportion of Th17/Treg cells and Th1/Th2 | ||
| Raw264.7 | Decreases both mRNA and protein levels of TNF-α, IL-1β, IL-6, IL-23, and IL-17A; inhibits NF-κB p65 and COX-2 expression; suppresses iNOS and NO | [ | |
| BALB/c mice/ | Reduces PASI, infiltration of macrophage, T cells, and neutrophil, and IL-1β, IL-17A, IL-23, and IL-6 expression | ||
| Luteolin-7-glucoside | HEKn | Modifies cell cycle, energy, fatty acid, and redox metabolism; increases KRT10 expression and cortisol levels; decreases PGE2 level | [ |
| C57BL/6 mice/imiquimod | Reduces skin psoriasis-like lesions, Ki67 and p63; increases KRT10, TGase-1, and Loricrin; modulates expression of STAT3 | ||
| Baicalein | HaCaT cells | Inhibits cell growth; causes growth arrest in G0/G1phase; induces morphological differentiation Ca2+ dependent; increases KRT10 and KRT1 expression and ERK phosphorylation; activates TRPV4 | [ |
| Baicalin | BALB/c and ICR mice/DNFB | Reduces psoriatic symptoms, edema, and inflammatory cell infiltration; increases orthokeratosis | [ |
| BALB/c mice/imiquimod | Reduces psoriatic symptoms, PASI, histological damage, expression of TNF-α, IL-23, IL-22, and IL-17A, and γδT cells infiltration | [ | |
| Chrysin | NHEKs | Attenuates phosphorylation of JNK, ERK, and p38 kinase; decreases p-STAT3 and p-JAK2; suppresses CCL20 and AMPs expression | [ |
| BALB/c mice/imiquimod | Reduces psoriatic symptoms, PASI, histological damage, TEWL, erythema, blood flow, and thickness; increases the content of surface skin hydration | ||
| Tangeretin | HaCaT cells | Inhibits the nuclear translocation of NF-κB p65 and HIF-1α | [ |
| BALB/c mice/PMA-induced ear inflammation | Reduces psoriatic symptoms, histological damage, PMA-induced hyperplasia; down-regulates the production of IL-1β, IL-6, IL-4, TNF-α, IFN-γ, PGE2, COX-2, MIP-2, MCP-1, KC, TRX, nNOS, iNOS, eNOS, MMP-9, MMP-2, TLR4, VEGF, p-Akt, p-p38, p-JNK, p-ERK1/2, NF-κB p65, NF-κB p50, IκBα, IKK-γ, and HIF-1α; |
Anti-psoriatic activity of the flavonols present in propolis.
| Flavonols | Model/Psoriasis Inducer | Activities | Ref. |
|---|---|---|---|
| Quercetin | Albino mice | Increases orthokeratosis; decreases granular layer of the epidermis; presents anti-inflammatory effects | [ |
| BALB/c mice/imiquimod | Reduces psoriatic symptoms, PASI, temperature of the psoriasis-like lesions, histological damage, IL-17, IL-6, and TNF-α; increases SOD, CAT, and GSH; downregulates the expression of RelB, IKKα, and NIK; upregulates TRAF3 expression | [ | |
| Fisetin | NHEKs, A431, HaCaT, PBMCs and FTRHSP | Inhibits cells growth of NHEKs, A431, HaCaT; on NHEKs induce TGase activity; increases nuclear expression of AP-1 factor subunits (factor Fos (Fos B, c-Fos, and Fra-1/2) y Jun (JunD, JunB, and c-Jun)); suppresses TNF-α-induced activation of MAPK and PI3K/Akt/mTOR pathway; reduces TNF-α, IL-1β, IL-1α, IL-8, IL-6, and TGF-α; in PBMCs inhibits IL-17A and IFN-γ mRNA accumulation; in FTRHSP suppresses expression of desmoglein-1, TGase-1, filaggrin, involucrin, and KRT10, IL-17A, p-p70S6K, and psoriasin markers | [ |
| Kaempferol | T cells | Suppresses T cells proliferation; inhibits phosphorylation of p70S6K downstream of the mTOR signaling | [ |
| BALB/c mice/imiquimod | Reduces psoriatic symptoms, histological damage, PASI, CD3+T cell infiltration, IL-17A+CD4+ or RORγt+CD4+ T cells, mRNA expression of TNF-α, IL-6, and IL-17A; inhibits p-NF-κB p65 expression; promotes CD4+FoxP3+ Treg generation |
Main anti-psoriatic effects of flavanones, flavan-3-ols, and isoflavones in different study models.
| Flavonoids | Model/Psoriasis Inducer | Activities | Ref. |
|---|---|---|---|
| Naringenin | hPBMCs | Suppress LPS-induced serum TNF-α levels | [ |
| BALB/c mice/imiquimod | Reduces psoriatic symptoms, PASI, histological damage, and TEWL; inhibits neutrophil migration and IL-6 | [ | |
| Hesperidin | HaCaT cells | Inhibits LPS-induced cell proliferation; down-regulates expression of p-ERK1/2 | [ |
| BALB/c mice/imiquimod | Reduces psoriatic symptoms, PASI, histological damage, expression of involucrin, IL-22, IL-23, IL-17, TNF-α, and IL-1β; decreases p-ERK1/2 level | ||
| EGCG and EGCG nanoparticles | NHEKs | Induces differentiation; increases involucrin, TGase-1, KRT10, and caspase-14; inhibits CXCL2, TGF-β, TNF-α, IL-8, IL-6, and IL-1β | [ |
| BALB/c mice/imiquimod | Reduces psoriatic symptoms and loricrin expression; decreases Ki67 expression, infiltration CD4+ T lymphocytes, and tissue vascularization; restores JunB and KRT10 expression; inhibits expression of IL-1β and TNF-α | ||
| EGCG | Reduces psoriatic symptoms, PASI, histological damage, lipoperoxidation; decreases CD4+ T cells infiltration, IL- 23, IL-22, IL-17F, and IL-17A levels; increases CAT and SOD bioactivities | [ | |
| Genistein | HaCaT cells | Decreases MCP-1, VEGFA, TNF-α, IL-23, IL-8, and IL-1β; inhibits IκBα phosphorylation; decreases NF-κB level | [ |
| BALB/c mice/imiquimod | Reduces histological damage, CD45 inflammatory cell infiltration, TNF-α, IL-6, IL-1β, CCL2, IL-23, and IL-17; suppresses STAT3 phosphorylation |